You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
2026 › April › 06
Soleno
3 months ago
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment ⊖
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
page 1 of 1